ABSTRACT
INTRODUCTION
Breast cancer is the second leading cause of cancerrelated deaths in women and is the most common cancer in females, accounting for 23% of all cancer cases [1, 2] . Triple-negative breast cancer (TNBC) is a subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, as confirmed by immunohistochemistry or fluorescent in situ hybridization.
TNBC is associated with a poor prognosis due to its more aggressive behavior, higher recurrence, generation of more metastases, and fewer treatment options compared with other breast cancer subtypes [3] . Cytotoxic chemotherapy remains the mainstay of treatment for TNBC, and metastatic organ sites and disease-free interval (DFI) are thought to be prognostic factors of advanced disease [4] .
Serum lactate dehydrogenase (LDH) converts pyruvate to lactate in the cytoplasm during glycolysis and is thought to be a marker of tissue injury, inflammation, Research Paper www.impactjournals.com/oncotarget hemolysis, and myocardial damage [5] [6] [7] . In addition, abnormally high serum levels of LDH are predictive of prognosis in various malignancies [8] and are associated with breast cancer patient survival [4, [9] [10] . Nevertheless, the association between advanced TNBC and serum LDH is not well understood; thus, we conducted an explorative study to determine the potential relationship.
RESULTS
All patients received a platinum-based or taxanebased regimen as first-line treatment (Table 1 ). In our daily practice, the previously used drugs will not be reapplied in those patients experiencing relapse within 3 months after completing neo-adjuvant or adjuvant chemotherapies. (Table 3) , and DFI, number of metastatic sites, liver, skeletal and lymph node metastases, chemotherapeutic response, and baseline serum LDH and LDH changes were potential prognosis factors for OS (Table 4 ). PFS and OS of different groups are shown in Figures 1 and 2 . Patients with abnormally high baseline serum LDH levels above normal had significantly shorter OS (unadjusted HR: 2.192, 95% CI: 1.504-3.194, P < 0.001) but no difference in PFS (unadjusted HR: 1.237, 95% CI: 0.837-1.828, P = 0.284) compared to those with normal baseline serum LDH levels ( Figure 1 ).
Using the Cox regression model, we found that the independent prognostic factors of PFS for advanced TNBC patients were DFI (≤ 12 mon vs. > 12 mon, HR: 1.976, 95% CI: 1.300-3.003, P = 0.001), chemotherapeutic response (no vs. yes, HR: 2.684, 95% CI: 1.787-4.032, P < 0.001), and LDH changes (Group 3 vs. Group 1, HR: 0.517, 95% CI: 0.278-0.963, P = 0.038; Group 4 vs. Group1, HR: 0.346, 95% CI: 0.204-0.587, P < 0.001). The difference in OS among the four groups defined by LDH changes in Figure 2 disappeared when adjusted with other variables identified by univariate analysis with P < 0.1 (DFI, number of metastatic sites, liver metastases, skeletal metastases, lymph nodes metastases, chemotherapy response, and baseline LDH level 
DISCUSSION
Advanced TNBC is highly aggressive, with a median PFS of 3-7.7 months and a median OS of about 1 year [11] [12] [13] [14] [15] . Similarly, the PFS and OS in this study population were 7.9 months (95% CI: 6.3-9.5 months) and 15.1 months (95% CI: 13.2-17.0 months), respectively.
LDH is required for aerobic glycolysis and can reversibly catalyze conversion of pyruvate to lactate. Recently, serum LDH has been reported to be important in numerous malignances and is documented to be 1 of 5 risk factors in the International Prognostic Index for the diffuse large B-cell lymphoma [16] . Baseline serum LDH has also been included in TNM staging system of melanoma [17] . Furthermore, high serum LDH levels are associated with adverse outcomes in lung cancer [18] , esophageal squamous cell carcinoma [19] , gastric [20] and pancreatic cancer [21] and renal cell carcinoma [22] . A recent systematic review and meta-analysis identified 76 studies of various solid tumors in which higher LDH was associated with shorter OS (HR = 1.7, P < 0.00001) and shorter PFS (HR = 1.75, P < 0.00001) [23] . In addition, LDH is reported to be a promising predictor of effectiveness of targeted agents such as bevacizumab, vatalanib, and sorafenib [24] [25] [26] .
Although multiple studies have demonstrated the prognostic value of LDH in various malignances, the underlying pathophysiological mechanism remains unclear. LDH is possibly translationally controlled by HIF-1 and myc, and thus is regulated by the key oncogenic processes such as the phosphatidylinositol 3-kinase/AKt/TORC1/ HIF pathway or by myc overexpression [27] [28] [29] . There is a positive feedback loop between HIF and LDH, and each can stimulate the activation of the other [30] . Moreover, HIF overexpression can activate vascular endothelial growth factor-A [31] , thereby linking glycolysis and LDH to angiogenesis and cancer progression [32] .
Here, we exploratively studied the association between serum LDH and prognosis of advanced TNBC patients, and found that abnormal serum LDH levels were significantly associated with metastatic sites and younger age of cancer onset. Greater metastatic sites reflect heavier www.impactjournals.com/oncotarget TNBC patients with abnormal baseline serum LDH levels (n = 54) and those with normal baseline serum LDH levels (n = 77) in (A) (unadjusted HR: 1.237, 95% CI: 0.837-1.828, P = 0.284). Advanced TNBC patients with abnormal baseline serum LDH levels (n = 54) had significantly poorer OS than those with normal baseline levels (n = 77) in (B) (unadjusted HR: 2.192, 95% CI: 1.504-3.194, P < 0.001). www.impactjournals.com/oncotarget tumor burden and younger patients tend to have poorer prognosis as compared to older patients [33, 34] , and our data indicated that LDH might negatively influence the progression of advanced TNBC. However, menopausal status, liver, lung, skeleton, lymph node metastases and DFI were shown to have no effect on baseline serum LDH. Few studies describe the prognostic value of serum LDH in breast cancer. Yamamoto's group [4] reported that abnormal serum LDH was associated with poorer survival among metastatic breast cancer subjects and Brown's group [10] confirmed that LDH was strongly correlated with survival in breast cancer patients with bone metastases. Moreover, Liu and colleague [9] reported that greater LDH predicted worse 5-year OS in non-metastatic stage II and III breast cancers. We also found significant associations between serum LDH level and prognosis of advanced TNBC patients. However, an independent prognostic value was only found with LDH changes between baseline and post-treatment for PFS and baseline LDH for OS. Patients with post-treatment serum LDH level that decreased to normal and patients who had both normal baseline and post-treatment serum LDH had significantly longer PFS than patients whose post-treatment serum LDH were abnormal and higher than baseline. In addition, patients with normal baseline serum LDH had significantly longer OS than patients with abnormal baseline serum LDH. As Logistic regression model with multiple variables (age, menopausal status, number of metastatic sites, liver metastases, lung metastases, skeletal metastases, lymph node metastases, and disease-free survival) mentioned earlier, abnormal serum LDH might have a negative effect on the progression of advanced TNBC, and this may partially explain why patients with normal posttreatment serum LDH level had better survival outcomes.
Decreases in LDH may reflect cessation of tumor growth, while increases are associated with tumor progression [35] . In this study, most of the 28 patients with post-treatment LDH that decreased to normal after chemotherapy, had a good response to chemotherapy (PR or CR), and ORR was significantly higher than that in patients with abnormal post-treatment serum LDH higher than baseline. This suggested that LDH changes after chemotherapy reflect tumor regression. However, no significant advantages were found for patients with post-treatment LDH that did not decline to normal and patients with both normal baseline and post-treatment LDH. Likely tumor regression occurred with the rapid and dramatic fall in LDH and this might explain why patients whose post-treatment LDH decreased to normal had longer PFS.
Therefore, serum LDH may be a useful biomarker to predict survival and chemotherapeutic response in advanced TNBC patients. More research is needed to confirm these findings and to understand the mechanism underlying LDH and tumor progression.
MATERIALS AND METHODS
A retrospective review was undertaken with female patients with advanced TNBC (n = 131) who received first-line chemotherapy at Fudan University Shanghai Cancer Center between 2005 and 2013. Patients were included if they had pathological confirmation of TNBC, biopsy or radiological confirmation of tumor recurrence or distant metastasis, good ECOG performance status, and available data on baseline and post-treatment serum LDH levels (see patient characteristics in Table 1 ). Patients were excluded if they had complications from other types of malignancies, no evidence of tumor recurrence or distant metastasis, acute heart failure, or severe renal or liver dysfunction.
Patients' medical charts were reviewed to obtain data about clinical features, treatment information, and serum LDH levels. Menopause status was defined according to the National Comprehensive Cancer Network [36] ). Serum LDH levels were measured using the Roche Cobas 8000 system (Roche, Indianapolis, IN, USA). All patients were told to fast after midnight on the day of the blood test. Baseline serum LDH levels were measured within 2 weeks before administering first-line chemotherapy. If multiple measurements were taken, the average of the measurements was used. Patients were stratified to normal baseline LDH (≤ 250 IU/L) and abnormal baseline LDH (>250 IU/L) groups. Post-treatment serum LDH measurements were conducted after two cycles of firstline chemotherapy. According to changes between baseline and post-treatment LDH values, patients were divided into four groups: Group 1 included patients with abnormal post-treatment serum LDH levels higher than baseline; Group 2 included patients with post-treatment serum LDH levels that decreased but did not return to normal; Group 3 included patients with post-treatment serum LDH levels that decreased to normal; and Group 4 included patients with normal baseline and post-treatment LDH levels. Tumor responses to chemotherapy (chemotherapeutic response) were assessed and graded as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the revised RECIST guideline (version 1.1) [37] . Clinical response was defined as either CR or PR. Survival information was collected from medical records or telephone interviews. The diseasefree interval (DFI) was defined as the period between surgical resection and diagnosis of tumor recurrence or distant metastasis. Progression-free survival (PFS) was defined as the period between the start of chemotherapy and the first time of documented PD. Overall survival (OS) was defined as the period between diagnosis of local recurrence or distant metastasis and death or last followup. Objective response rate (ORR) was defined as the percent of patients with CR and PR.
We used SPSS 21.0 statistical software to analyze data, and a two-tailed p value < 0.05 was considered statistically significant. A multiple comparisons analysis was not mandatory because the goal of this exploratory analysis was to identify hypotheses that could be subject to more rigorous future examinations. A chi-squared test was used to investigate the association between baseline serum LDH levels and clinical features, as well as the association between various risk factors and chemotherapy response. Logistic regression was used to analyze the association between serum LDH levels and potentially relevant factors, as well as the association between the chemotherapeutic response and potential relevant factors. PFS and OS were determined according to the KaplanMeier method, and intergroup comparison according to the variables in Table 1 was performed by the log-rank test. Subsequently, the relevant variables identified by univariate analysis with a significant association with PFS and OS (P < 0.1) and two clinically potentially important variables (age and type of first-line treatment) were analyzed using the Cox regression model to determine the independent prognostic factors for PFS and OS.
